Cellularis Biomodels, Lda
Desconocido
EdiGenT: New Prime Editing and non-viral delivery strategies for Gene Therapy
CELLULARIS BIOMODELS LDA
participó en un
HORIZON EUROPE:
HORIZON-EIC-2021-PATHFINDERCHALLENGES-01
Genome editing technologies based on CRISPR/Cas systems allow targeted genomic modification with unprecedented precision and have emerged as...
2022-09-13 - 2027-09-30 | Financiado
2022-09-13 - 2027-09-30 | Financiado
INSPIRE: Developing novel inhaled bioengineered Extracellular Vesicle RNA based advanced therapeutics, delive...
CELLULARIS BIOMODELS LDA
participó en un
HORIZON EUROPE:
HORIZON-HLTH-2021-TOOL-06
Lung cancer (LC) treatments have advanced in recent years with the advent of genetic profiling and immunotherapy. However, LC is a complex h...
2022-05-24 - 2025-05-31 | Financiado
2022-05-24 - 2025-05-31 | Financiado
* No se disponen de datos de la empresa actual.